Alexander P Cole

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2418295/publications.pdf

Version: 2024-02-01

112	1,787	304602	330025
papers	citations	22 h-index	37 g-index

116	116	116	2836
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. European Urology, 2016, 70, 837-845.	0.9	178
2	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Network Open, 2020, 3, e2030072.	2.8	87
3	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€"Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	0.8	70
4	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2018, 199, 1417-1425.	0.2	70
5	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. European Urology, 2018, 73, 374-382.	0.9	62
6	Association of Care at Minority-Serving vs Nonâ€"Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Network Open, 2019, 2, e187633.	2.8	60
7	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2018, 4, 225.	3.4	58
8	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscleâ€invasive carcinoma of the bladder: Does histologic subtype matter?. Cancer, 2019, 125, 1449-1458.	2.0	56
9	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 125-136.	2.0	53
10	Where Is the Value in Ambulatory Versus Inpatient Surgery?. Annals of Surgery, 2021, 273, 909-916.	2.1	51
11	Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience. Prostate, 2015, 75, 191-199.	1.2	49
12	Secondary data sources for health services research in urologic oncology. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 165-173.	0.8	48
13	Secondary data analysis. Current Opinion in Urology, 2017, 27, 354-359.	0.9	44
14	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. European Urology, 2019, 75, 552-555.	0.9	43
15	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. Journal of Urology, 2016, 196, 1090-1095.	0.2	42
16	Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer and Prostatic Diseases, 2020, 23, 81-87.	2.0	39
17	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Network Open, 2020, 3, e201839.	2.8	37
18	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2018, 200, 573-581.	0.2	31

#	Article	IF	Citations
19	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. Journal of Urology, 2019, 201, 735-741.	0.2	31
20	Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU International, 2018, 121, 811-818.	1.3	27
21	Access denied: The relationship between patient insurance status and access to highâ€volume hospitals. Cancer, 2021, 127, 577-585.	2.0	26
22	The Rise of Robotic Surgery in the New Millennium. Journal of Urology, 2017, 197, S213-S215.	0.2	23
23	Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Network Open, 2019, 2, e194634.	2.8	23
24	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e9-504.e17.	0.8	21
25	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	0.8	21
26	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1049-1058.	2.3	21
27	Reassessing the value of highâ€volume cancer care in the era of precision medicine. Cancer, 2018, 124, 1319-1321.	2.0	20
28	Trends in Breast, Colorectal, and Cervical Cancer Incidence Following the Affordable Care Act. JAMA Oncology, 2018, 4, 128.	3.4	20
29	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Annals of Surgical Oncology, 2019, 26, 297-305.	0.7	20
30	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome raceâ€based differences in survival?. Cancer, 2019, 125, 1319-1329.	2.0	20
31	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65Âyears. Cancer, 2020, 126, 496-505.	2.0	19
32	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 163-167.	0.6	19
33	Impact of health literacy on shared decision making for prostateâ€specific antigen screening in the United States. Cancer, 2021, 127, 249-256.	2.0	19
34	Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. JAMA Network Open, 2020, 3, e1919185.	2.8	18
35	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 410-418.	2.0	17
36	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 78.e13-78.e19.	0.8	16

#	Article	IF	Citations
37	Postoperative mortality 90 days after robotâ€assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide populationâ€based study. BJU International, 2016, 118, 302-306.	1.3	14
38	On higher ground: ethical reasoning and its relationship with error disclosure. BMJ Quality and Safety, 2013, 22, 580-585.	1.8	13
39	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	1.2	12
40	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer and Prostatic Diseases, 2020, 23, 179-183.	2.0	12
41	Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. Cancer, 2021, 127, 2714-2723.	2.0	12
42	Use of Preventive Health Services Among Cancer Survivors in the U.S.. American Journal of Preventive Medicine, 2018, 55, 830-838.	1.6	11
43	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e1060-e1068.	0.9	11
44	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clinical Genitourinary Cancer, 2019, 17, e488-e493.	0.9	11
45	Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. JCO Oncology Practice, 2021, 17, e654-e665.	1.4	11
46	The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. Urology, 2016, 94, 70-76.	0.5	10
47	Weighing the evidence from surgical trials. BJU International, 2017, 119, 659-660.	1.3	10
48	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICAREÂ® Military Database. Journal of Urology, 2017, 198, 1295-1300.	0.2	10
49	Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?. Urology, 2021, 147, 199-204.	0.5	9
50	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. Journal of Oncology Practice, 2019, 15, e547-e559.	2.5	8
51	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	2.0	8
52	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 413-418.	0.6	8
53	Measuring What Matters: Patient-Reported Outcome and Experience Measures for Men Undergoing Radical Prostatectomy. European Urology Focus, 2021, 7, 913-915.	1.6	8
54	Digital technologies in cancer care: a review from the clinician's perspective. Journal of Comparative Effectiveness Research, 2022, , .	0.6	8

#	Article	IF	Citations
55	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. European Urology Focus, 2016, 2, 3-9.	1.6	7
56	Contemporary trends in the utilisation of radical prostatectomy. BJU International, 2018, 122, 726-728.	1.3	7
57	Association of Affordable Care Act-related Medicaid expansion with variation in utilization of surgical services. American Journal of Surgery, 2020, 220, 441-447.	0.9	7
58	Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate Specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data. Journal of Urology, 2022, 207, 993-1000.	0.2	7
59	Association of Androgen Deprivation Therapy With Alzheimerâ€™s Disease: Unmeasured Confounders. Journal of Clinical Oncology, 2016, 34, 2801-2803.	0.8	6
60	Testosterone replacement therapy is associated with an increased risk of urolithiasis. World Journal of Urology, 2019, 37, 2737-2746.	1.2	6
61	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. European Urology Oncology, 2019, 2, 349-354.	2.6	6
62	Comparison of testis cancerâ€specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU International, 2019, 123, 385-387.	1.3	6
63	Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. Urology, 2020, 140, 115-121.	0.5	6
64	Geographic Variability, Time Trends and Association of Preoperative Magnetic Resonance Imaging with Surgical Outcomes for Elderly United States Men with Prostate Cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Journal of Urology, 2022, 208, 609-617.	0.2	6
65	Assessing robot-assisted laparoscopic prostatectomy. Lancet, The, 2017, 389, 799.	6.3	5
66	The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e9-575.e18.	0.8	5
67	Re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. J Clin Oncol 2018;36:1192â€“8. European Urology Oncology, 2019, 2, 222-223.	2.6	4
68	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 130.e17-130.e24.	0.8	4
69	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. Journal of Comparative Effectiveness Research, 2021, 10, 733-741.	0.6	4
70	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e10.	0.8	4
71	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. Journal of Urology, 2019, 201, 728-734.	0.2	4
72	Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Annals of Surgical Oncology, 2020, 27, 1929-1936.	0.7	3

#	Article	IF	Citations
73	Care Setting as a Modifiable Predictor of Perioperative Cost and Outcomes following Elective Urinary Stone Surgery. Urology Practice, 2020, 7, 259-265.	0.2	3
74	Impact of Accountable Care Organizations on Prostate Cancer Screening and Biopsies in the United States. Urology Practice, 2019, 6, 159-164.	0.2	3
75	Observational Studies to Contextualize Surgical Trials. European Urology, 2016, 70, 231-232.	0.9	2
76	Re: Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. European Urology, 2016, 69, 963-964.	0.9	2
77	New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (<scp>COX</scp>) blockers in erectile dysfunction. BJU International, 2016, 117, 385-386.	1.3	2
78	Challenging Residual Contamination of Instruments for Robotic Surgery in Japan. Infection Control and Hospital Epidemiology, 2017, 38, 501-502.	1.0	2
79	Risk factors for metastatic prostate cancer: A sentinel event case series. Prostate, 2017, 77, 1366-1372.	1.2	2
80	Adoption of robotic surgery: driven by market competition or a desire to improve patient care?. Lancet Oncology, The, 2018, 19, e66.	5.1	2
81	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Canadian Urological Association Journal, 2018, 13, 32-37.	0.3	2
82	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1644-1650.	1.3	2
83	Temporal trends in the incidence of distantâ€stage bladder cancer among young individuals. International Journal of Urology, 2021, 28, 704-705.	0.5	2
84	Limitations of using the National Cancer Database to examine the effect of policy change on stage at presentation at the population level. Journal of the American Academy of Dermatology, 2021, 85, e195-e196.	0.6	2
85	Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection. World Journal of Men?s Health, 2020, 38, 32.	1.7	2
86	A Nationwide Survey of Prostate Specific Antigen Based Screening and Counseling for Prostate Cancer. Urology Practice, 2017, 4, 210-217.	0.2	1
87	Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol 2017;72:488â€“9. European Urology, 2017, 72, 489-491.	0.9	1
88	Low rates of bone density testing in prostate cancer survivors on androgenâ€deprivation therapy: where do we go from here?. BJU International, 2018, 121, 492-493.	1.3	1
89	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 400.e15-400.e22.	0.8	1
90	Letâ€™s Follow the Golden Mean: Using Magnetic Resonance Imaging to Determine the Need for Biopsy in Men on Active Surveillance. European Urology Oncology, 2021, 4, 235-236.	2.6	1

#	Article	IF	Citations
91	Understanding the roles of randomized trials for robotic prostatectomy. Annals of Translational Medicine, 2016, 4, 467-467.	0.7	1
92	Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer. British Journal of Radiology, 2022, 95, 20210840.	1.0	1
93	Hormone Treatment of Prostate Cancer:. Urologic Clinics of North America, 2022, 49, 309-321.	0.8	1
94	Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospital systems serving health disparity populations.. Journal of Clinical Oncology, 2022, 40, 6555-6555.	0.8	1
95	Editorial Comment. Urology, 2016, 87, 86-87.	0.5	0
96	Re: Phillip J. Gray, Chun Chieh Lin, Matthew R. Cooperberg, Ahmedin Jemal, Jason A. Efstathiou. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol 2017;71:729â€“37. European Urology, 2017, 71, e181-e182.	0.9	0
97	Editorial Comment. Journal of Urology, 2017, 197, 1206-1207.	0.2	0
98	Evaluation of magnetic resonance imaging and targeted biopsy: The difficulty of finding the right reference standard. Cancer, 2018, 124, 1299-1300.	2.0	0
99	Health Services Research and Robotic Surgery. , 2018, , 235-252.		0
100	Contemporary qualityâ€ofâ€life scores provide a key foundation for highâ€quality cancer research. BJU International, 2018, 122, 720-721.	1.3	0
101	Reply to Amar U. Kishan, William Hall, and Daniel Spratt's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552â€“5 Comparing Apples to Oranges: A Self-fulfilling Prophecy?. European Urology, 2019, 75, e135-e136.	0.9	0
102	Trimodal Therapy for Bladder Cancer. JAMA Surgery, 2019, 154, e191637.	2.2	0
103	Are historical studies relevant in the setting of grade migration?. BJU International, 2019, 123, 375-376.	1.3	0
104	Re: Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Health Care Costs, 2003 to 2015. European Urology, 2019, 75, 696-697.	0.9	0
105	Leveraging the Full Potential of Clinical Registries. European Urology Focus, 2019, 5, 109-110.	1.6	0
106	AUTHOR REPLY. Urology, 2020, 140, 121.	0.5	0
107	Using Cox Regression to Develop Linear Rank Tests with Zero-Inflated Clustered Data. Journal of the Royal Statistical Society Series C: Applied Statistics, 2020, 69, 393-411.	0.5	0
108	A New Era in Surgical Evaluationâ€”What Is at Stake?. JAMA Surgery, 2021, 156, e206360.	2.2	0

#	Article	IF	Citations
109	â€˜Case of the Monthâ€™ from Brigham and Womenâ€™s Hospital, Boston, MA, USA: a 70â€yearâ€old man with lung cysts and bilateral renal masses. BJU International, 2020, 126, 428-432.	1.3	0
110	Editorial Comment. Journal of Urology, 2022, , 101097JU0000000000000268501.	0.2	0
111	Risk and predictors of ipilimumab-associated cardiac adverse events among patients treated for melanoma: A national cohort analysis.. Journal of Clinical Oncology, 2022, 40, e14592-e14592.	0.8	0
112	Association Between Alcohol Intake and Prostate Specific Antigen Screening: Results from a National Behavioral Survey. Urology, 2022, , .	0.5	0